18.4 Quality Management, Risk & Tissue Management

Continuous Quality Improvement (CQI) In The Blood Bank

CQI is the structured, ongoing effort to identify and reduce process variation before it causes patient harm, distinct from routine daily QC, which confirms a single test result is valid. SBB-level quality programs run on a PDCA/PDSA cycle (Plan-Do-Check/Study-Act) and track defined quality indicators specific to transfusion medicine:

When an indicator trends unfavorably, the team performs a structured root-cause analysis (RCA), using the "5 Whys" or a fishbone/Ishikawa diagram, to trace the failure to its origin, then documents a corrective and preventive action (CAPA) plan and re-measures the indicator to confirm the fix worked. Benchmarking against AABB Standards, CAP peer-comparison data, or internal historical baselines helps a manager judge whether an indicator value represents a real problem or normal variation.

IQCP: An Alternative To Default QC Frequency

The Individualized Quality Control Plan (IQCP) is a CLIA option allowing a laboratory to design a QC frequency and process tailored to its own testing risk instead of following the manufacturer's or regulation's default QC schedule. An IQCP has three required components:

1. Risk Assessment (RA) — a systematic evaluation of every point in the testing process (specimen, environment, reagent, test system, testing personnel, and reporting) where an error could occur, and the likelihood and severity of each.
2. Quality Control Plan (QCP) — the specific QC frequency, materials, and acceptable-range criteria selected to control the risks identified, which may differ from, but must be at least as rigorous as, the manufacturer's minimum.
3. Quality Assessment (QA) — ongoing monitoring that confirms the QCP is actually controlling risk over time; if quality indicators worsen, the RA and QCP must be revisited.

A common blood bank application is antisera or reagent red cell QC: rather than testing every reagent lot on every day of use, a documented IQCP might justify QC at first use of a new lot or shipment plus defined ongoing intervals, supported by the RA showing stable historical performance. An IQCP is optional; a laboratory may instead simply follow the default regulatory or manufacturer QC frequency without building one, but if used, an IQCP must be fully documented and reassessed whenever a component of testing changes, such as a new lot, instrument, or testing location.

Risk Management And Medical-Legal Issues

Blood bank risk management extends beyond internal RCA into regulatory and legal reporting obligations unique to transfusion medicine:

• Fatality reporting — under 21 CFR 606.170, a blood establishment must report a transfusion-related fatality to the FDA as soon as possible, followed by a written report within 7 days. This is a hard regulatory deadline tested directly on the exam.
• Hemovigilance — participation in national biovigilance/hemovigilance surveillance tracks adverse reactions and near-miss events across facilities to identify systemic risks beyond any single hospital's experience.
• Informed consent — patients, or their legal representative, must be informed of the risks, benefits, and alternatives to transfusion before a non-emergency transfusion, and this consent must be documented; emergency transfusion without prior consent is permitted when delay would endanger the patient, with documentation of the emergency justification.
• Chain of custody — forensic or legal specimens, such as paternity testing or alleged transfusion-transmitted infection investigations, require an unbroken, signed record of every person who possessed the specimen, distinct from routine specimen handling.
• Record retention — AABB Standards and FDA regulations (21 CFR 606.160) require blood bank and transfusion records to be retained for a minimum of 10 years, longer than the retention period for many other clinical laboratory records, and certain donor-specific deferral records must be retained indefinitely to prevent an inappropriately deferred donor from being accepted elsewhere.

Tissue Storage And Distribution: A True SBB Differentiator

Because many blood centers and hospital transfusion services also distribute human tissue, the SBB content guideline, unlike the BB technologist guideline, includes tissue-banking regulation. Human tissue for transplantation is regulated under 21 CFR Part 1271 as a human cell, tissue, and cellular/tissue-based product (HCT/P), and accredited tissue banks follow American Association of Tissue Banks (AATB) standards, a separate accrediting body from AABB, though many facilities hold both accreditations.

Key differences an SBB must know:

• Donor eligibility determination for tissue follows its own screening and testing requirements, including infectious-disease testing and medical/social history review, that parallel but are not identical to blood donor eligibility criteria.
• Storage temperature is tissue-specific and validated, not uniform: viable HPC (hematopoietic progenitor cell) products are typically cryopreserved and stored at ≤-80°C, often in liquid nitrogen vapor phase, while musculoskeletal tissue is stored frozen at a different validated range, and certain tissues may be stored refrigerated depending on the processing method.
• Traceability must be maintained from donor through processing, storage, and distribution to the final recipient or final disposition, supporting recall and biovigilance investigations if a tissue-transmitted adverse event is later identified, mirroring blood component traceability but under the distinct tissue regulatory framework.
• FACT (Foundation for the Accreditation of Cellular Therapy) accreditation applies specifically to programs collecting, processing, and administering cellular therapy products such as HPC products, overlapping with SBB's therapeutic-apheresis and cellular-therapy content.

Exam items testing this section typically ask you to identify the correct regulation, retention period, reporting deadline, or accrediting body for a described scenario — precision on the specific number or name is what separates a correct answer from a plausible-sounding distractor.